title: Plasma pentosidine levels in uremic patients before and after hemodialysis.
abstract: Pentosidine, a fluorescent cross-link, is one of the advanced glycosylation end-products. It accumulates in human tissues, plasma and urine in diabetic and uremic patients. Using SP-Sephadex C-25 in the pretreatment for reversed-phase HPLC, we determined pentosidine levels in plasma before and after hemodialysis using cuprophane membranes from 18 patients (9 diabetic, 9 nondiabetic) with end-stage renal disease, as well as examined the hemodialysis efficiency of plasma pentosidine. We also measured beta 2-microglobulin levels in plasma before and after hemodialysis. The values of plasma pentosidine did not significantly change after hemodialysis. Also, plasma beta 2-microglobulin was not removed by hemodialysis. Hemodialysis efficiency of plasma pentosidine and beta 2-microglobulin was nil. In addition, there was a significant correlation between plasma levels of pentosidine and beta 2-microglobulin before hemodialysis in 116 uremic patients. The results indicated that hemodialysis could not eliminate pentosidine from plasma; therefore, pentosidine retention by the diseased kidney might be a major cause of elevated levels of pentosidine with uremia.
authors.affiliation: Department of Orthopedic Surgery, Hamamatsu University School of Medicine, Shizuoka, Japan.
authors.forename: M
authors.initials: M
authors.lastname: Takahashi
authors.forename: K
authors.initials: K
authors.lastname: Kushida
authors.forename: C
authors.initials: C
authors.lastname: Ishihara
authors.forename: M
authors.initials: M
authors.lastname: Denda
authors.forename: T
authors.initials: T
authors.lastname: Inoue
mesh_terms: D001120:Arginine / Q000031:analogs & derivatives* / Q000493:pharmacokinetics; D003432:Cross-Linking Reagents / Q000493:pharmacokinetics*; D003928:Diabetic Nephropathies / Q000097:blood / Q000628:therapy; D006031:Glycosylation; D006801:Humans; D007668:Kidney / Q000378:metabolism; D007676:Kidney Failure, Chronic / Q000097:blood* / Q000628:therapy; D008239:Lysine / Q000031:analogs & derivatives* / Q000493:pharmacokinetics; D008657:Metabolic Clearance Rate / Q000502:physiology; D006435:Renal Dialysis; D014511:Uremia / Q000097:blood* / Q000628:therapy; D001613:beta 2-Microglobulin / Q000378:metabolism
chemical_list: D003432:Cross-Linking Reagents; D001613:beta 2-Microglobulin; D001120:Arginine; C062187:pentosidine; D008239:Lysine